Content about Oxybutynin

May 8, 2013

Perrigo: $10 billion in Rx sales may switch OTC through 2018

There is as much as $10 billion in branded pharmaceutical sales that could make the switch from prescription-only to over-the counter in the next five years, suggested Joseph Papa, Perrigo chairman, CEO and president, to analysts on Tuesday.

January 25, 2013

Merck: FDA approves Oxytrol for Women, creating overactive bladder category in OTC

Merck on Friday announced the Food and Drug Administration has approved the switch of Oxytrol for Women (oxybutynin transdermal system, 3.9 mg/day) from prescription-only to nonprescription, creating a new category — overactive bladder in women — in the OTC area.

September 4, 2012

FDA's Nonprescription Drugs Advisory Committee to meet on Oxytrol Rx-to-OTC switch

According to a Food and Drug Administration post Friday, the FDA's Nonprescription Drugs Advisory Committee will be meeting Nov. 9 regarding the partial switch application from prescription to over the counter of Oxytrol (oxybutynin transdermal system), as submitted by MSD Consumer.

December 9, 2011

FDA approves Antares Pharma's overactive bladder drug

The Food and Drug Administration has approved a topical gel made by Antares Pharma for overactive bladder.

November 14, 2010

Out-of-pocket costs vary widely for branded, generic drugs

The often wide gap between what consumers will pay out of pocket for a branded...